Superconducting Self-Shielded and Zero-Boil-Off Magnetoencephalogram Systems: A Dry Phantom Evaluation.

Magnetoencephalography (MEG) systems are advanced neuroimaging tools used to measure the magnetic fields produced by neuronal activity in the human brain. However, they require significant amounts of liquid helium to keep the superconducting quantum interference device (SQUID) sensors in a stable superconducting state. Additionally, MEG systems must be installed in a magnetically shielded room to minimize interference from external magnetic fields. We have developed an advanced MEG system that incorporates a superconducting magnetic shield and a zero-boil-off system. This system overcomes the typical limitations of traditional MEG systems, such as the frequent need for liquid helium refills and the spatial constraints imposed by magnetically shielded rooms. To validate the system, we conducted an evaluation using signal source estimation. This involved a phantom with 50 current sources of known location and magnitude under active zero-boil-off conditions. Our evaluations focused on the precision of the magnetic field distribution and the quantification of estimation errors. We achieved a consistent magnetic field distribution that matched the source current, maintaining an estimation error margin within 3.5 mm, regardless of the frequency of the signal source current. These findings affirm the practicality and efficacy of the system.

Development of Continuous Line Scanning System Prototype for Proton Beam Therapy.

PURPOSE: Taking advantage of the continuous, high-intensity beam of the cyclotron at the National Cancer Center Hospital East, we developed a continuous line scanning system (CLSS) prototype for prostate cancer in collaboration with Sumitomo Heavy Industries, Ltd (Tokyo, Japan). MATERIALS AND METHODS: The CLSS modulates dose distribution at each beam energy level by varying scanning speed while keeping the beam intensity constant through a beam-intensity control system and a rapid on/off beam-switching system. In addition, we developed a beam alignment system to improve the precision of the beam position. The scanning control system is used to control the scanning pattern and set the value of the nozzle apparatus. It also collects data for monitoring and for cyclotron parameters and transmits information to the scanning power supplies and monitor amplifiers, which serve as the measurement system, and to the nozzle-control and beam-transfer systems. The specifications of the line scanning beam were determined in performance tests. Finally, a patient-specific dosimetric measurement for prostate cancer was also performed. RESULTS: The beam size, position, intensity, and scanning speed of our CLSS were found to be well within clinical requirements. The CLSS produced an accurate 3-dimensional dose distribution for clinical treatment planning. CONCLUSION: The performance of our new CLSS was confirmed to comply with clinical requirements. We have been employing it in prostate cancer treatments since October 23, 2015.